GlassScriptPhysician profile
Eugene D Kaplan
NPI 1215006531
$762.93
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.56 · 2020: $15.94 · 2021: $279 · 2022: $360 · 2023: $70.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $70.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $70.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $266.44 | 2021-2023 | |
| Tersera Therapeutics LLC | $158.96 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $62.81 | 2021 | |
| Collegium Pharmaceutical, INC. | $59.14 | 2022-2023 | Belbuca |
| Neurocrine Biosciences, INC. | $34.95 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $25.57 | 2021 | |
| Amgen INC. | $22.70 | 2022 | |
| Depuy Synthes Sales INC. | $21.84 | 2022 | |
| Pfizer INC. | $20.63 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.05 | 2022 | |
| Interventional Pain Technologies INC. | $18.82 | 2021 | |
| Livanova USA, INC. | $18.28 | 2021 | |
| Genzyme Corporation | $16.80 | 2022 | |
| Allergan, INC. | $15.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.